AMAM News and Press, Ambrx Biopharma Inc. American Depositary Shares (each representing seven) From 11/21/23

2023-11-21 05:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-10-26 10:46:42 ET More on Ambrx Biopharma Ambrx: Next-Generation Antibody-Drug Conjugates, Buying The Dip After ESMO Data Ambrx Biopharma: Potential With Recently Released Prostate Cancer Data Ambrx Biopharma falls after Phase 1/2 data for prostate cancer therap...

2023-10-24 11:23:00 ET Summary Ambrx Biopharma Inc. common stock experienced an irrational selloff following the Phase 1/2 ESMO data release for its ADC candidate ARX517, presenting a buying opportunity. The company's technology for next-generation ADCs has shown safety benefits a...

2023-10-23 18:50:27 ET Summary Ambrx Biopharma Inc. updated data of ARX517 for the treatment of patients with mCRPC shows encouraging anti-tumor activity with cohorts 6 through 8. In order to see if ARX517 can be improved upon for these patients with mCRPC, expansion of cohort 8 i...

2023-10-23 11:04:06 ET More on Ambrx Biopharma Promising Developments In Ambrx's Engineered Precision Biologics Historical earnings data for Ambrx Biopharma Financial information for Ambrx Biopharma For further details see: Ambrx Biopharma falls after Pha...

2023-10-23 08:31:36 ET Losers: Revolution Medicines ( RVMD ) -31% . Troika Media Group ( TRKA ) -21% . Li-Cycle Holdings Corp ( LICY ) -21% announces review of the rochester hub project . Mmtec ( MTC ) -18% . Palatin Technologies ( ...

Newly published data from the Phase 1 portion of the on-going Phase 1 / 2 APEX-01 trial provide the following key points: Multiple efficacy endpoints demonstrate consistent and promising anti-cancer activity at therapeutic doses of 2.0 – 2.88 mg/kg (Cohorts 6-8) in heavily pret...

2023-10-18 06:14:57 ET More on Ambrx Biopharma Promising Developments In Ambrx's Engineered Precision Biologics For further details see: Ambrx Biopharma files $300M mixed securities shelf

2023-10-17 08:25:48 ET Losers: Evelo Biosciences ( EVLO ) -40% announces top-line results from its Phase 2 clinical study with EDP2939 in moderate psoriasis . Purple Biotech Ltd ( PPBT ) -21% announces $5 Million registered direct offering. Netscout Systems...

2023-10-16 17:25:11 ET Gainers: Y-mAbs Therapeutics ( YMAB ) +6% . CrossFirst Bankshares ( CFB ) +4% . Iris Energy  ( IREN ) +4% . Vir Biotechnology ( VIR ) +3% . Service Properties Trust ( SVC ) +3% . Losers: NetSco...